Ryon Graf, PhD
@RyonGraf
Followers
585
Following
4K
Media
51
Statuses
2K
Biomedical scientist & ocean lover. Into diagnostics, biostatistics, & outcomes-based evidence. Employer: @FoundationATCG Opinions: my own. RT≠endorsement.
San Diego, CA
Joined July 2013
RT @PTarantinoMD: The results of SONIA are out on @Nature. 1L use of palbo did not improve PFS over 2L use, but led to more AEs & costs. An….
0
84
0
RT @wandering_gu: 🚨 New pub: real-world PARP-I response in mCRPC according to DDR alteration status. Huge credit to 💫 @UMichUrology chief….
0
5
0
RT @BrunaPellini: 🚨Happy to share our exciting #ctDNA monitoring research in metastatic NSCLC hot off the press @CCR_AACR 👇.
0
41
0
RT @FoundationATCG: In a letter to @CellPressNews' Cancer Cell, our scientists share new research demonstrating a consistent association be….
0
3
0
RT @wandering_gu: OS data from PROPEL (Olaparib + Abi) in 1st line mCRPC. 7 mo median OS benefit (p=0.054). But really driven by HRRm subgr….
0
8
0
RT @AzadOncology: @Ecastromarcos @ASCO #GU23 discussing Talapro-2 & Triton-3 abstracts. Ongoing Qs/challenges:. 1. Where will PARPi best fi….
0
5
0
RT @wandering_gu: Beautiful summary of mCRPC treatment options with recommended algorithms by @Silke_Gillessen #GU23
0
6
0
RT @DrRanaMcKay: Amazing data presented from Talapro-2 by @neerajaiims on the heals of Propel and Magnitude providing future support of PAR….
0
6
0
RT @ERPlimackMD: Surprised to hear such emphatic support of PFS wout OS benefit for PARPi in #prostatecancer when 1 in 4 on PARPi require o….
0
18
0
RT @tompowles1: Talapro-2 ⬆️ rPFS for talazoparib/enza in unselected CRPC with more benefit in HRR as with olaparib/abi. Titron-3 showed ru….
0
46
0
RT @shilpaonc: @Ecastromarcos delivers an elegant &. thoughtful discussion of TALAPRO2 @neerajaiims and TRITON3 @AlanBryce9 . We need to u….
0
4
0
RT @wandering_gu: Important take home slide from @Ecastromarcos on PARPi role in mCRPC. BRCA>HRRm>all comers>non-HRRm. #GU23
https://t.co….
0
8
0
RT @JCOPO_ASCO: 👀 Check out what’s popular this week in #JCOPO:. Tumor Fraction Correlates With Detection of Actionable Variants Across > 2….
0
5
0
RT @NatRevClinOncol: Study shows that plasma cfDNA tumour fraction is a pragmatic, independent prognostic biomarker across across pts with….
annalsofoncology.org
Genomic analysis of circulating tumor DNA (ctDNA) is increasingly incorporated into the clinical management of patients with advanced cancer. Beyond tumor profiling, ctDNA analysis also can enable...
0
16
0
RT @Annals_Oncology: This article in Annals of Oncology reports on the prognostic value of ctDNA fraction across different tumor types usin….
annalsofoncology.org
Genomic analysis of circulating tumor DNA (ctDNA) is increasingly incorporated into the clinical management of patients with advanced cancer. Beyond tumor profiling, ctDNA analysis also can enable...
0
12
0
RT @sidlipsey: Loving John Smoltz’s on-air hat tip to the late Tony Gwynn. I knew Gwynn did well against that Braves Hall of Fame ‘90s rota….
0
2
0
RT @StoverLab: Great collab evaluating hypothesis that ctDNA tumor fraction may be prognostic across cancers. Full 🧵to follow!. What a tea….
0
8
0
RT @shilpaonc: @GUONCGarciaJA gives a shoutout to @neerajaiims @umangtalking on their work on #SPOP mutations as a predictive biomarker in….
0
9
0
RT @MyriamChalabi: About the smile: the standing ovation also meant that people saw what I knew: behind every one of these bars is a patien….
0
250
0
RT @KlempnerSam: Ever since #ESMO22 @myESMO I have been seeing #ChalabiPlot all over. Found this one and the likely EFS curve in the woodp….
0
4
0